En medio de la campaña de Donald Trump para privar a Cuba de combustible y aislarla políticamente, los cubanos tienen cada vez menos opciones para salir de su isla gobernada por el comunismo. (Source: Bloomberg)
En medio de la campaña de Donald Trump para privar a Cuba de combustible y aislarla políticamente, los cubanos tienen cada vez menos opciones para salir de su isla gobernada por el comunismo. (Source: Bloomberg)
Roland Magnusson/iStock Editorial via Getty Images AstraZeneca ( AZN ) announced plans to seek accelerated approval for its rare disease therapy, Ultomiris, on Tuesday after the C5 complement inhibitor reached a key goal in a late-stage trial for immunoglobulin A nephropathy (IgAN), a kidney disease. Citing interim data from its I CAN Phase III trial, the Anglo-Swedish drugmaker said Ultomiris red...
Roland Magnusson/iStock Editorial via Getty Images AstraZeneca ( AZN ) announced plans to seek accelerated approval for its rare disease therapy, Ultomiris, on Tuesday after the C5 complement inhibitor reached a key goal in a late-stage trial for immunoglobulin A nephropathy (IgAN), a kidney disease. Citing interim data from its I CAN Phase III trial, the Anglo-Swedish drugmaker said Ultomiris reduced proteinuria with a statistically significant and clinically meaningful effect at Week 34 in adults with IgAN. A rare inflammatory disease, patients with IgAN show various immune-related signs and symptoms, including proteinuria, the presence of excessive amounts of protein in the urine. The global trial, designed to enroll nearly 510 patients with IgAN who are at risk of disease progression, tested Ultomiris as a late-line option. The 34-week reduction of proteinuria, measured as a 24-hour urine protein creatinine ratio (UPCR), was one of its primary endpoints. There were no new safety signals, and the intravenous therapy indicated a tolerability profile consistent with prior data, the company said. I CAN is set to continue until data for its other primary endpoint related to estimated glomerular filtration rate are analyzed at Week 106. Ultomiris is already approved in the U.S. and EU for rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. “We look forward to filing these data with regulatory authorities in key regions while, in parallel, advancing this Phase III trial towards completion,” said Marc Dunoyer, CEO of Astra’s ( AZN ) rare disease unit Alexion. More on AstraZeneca PLC AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns AstraZeneca: The Big China Bet AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy Astra posts another late-stage trial win for COPD therapy First generics to AstraZeneca’s Farxiga approved in U.S.
Shares of semiconductor lithography specialist ASML Holding (NASDAQ: ASML) have more than doubled over the last year -- crushing the performance of the broader tech sector and Nasdaq Composite . At $1,410 per share at the time of this writing, ASML would need to gain around 42% to surpass $2,000 per share, and 81% to become the first European company to surpass $1 trillion in market capitalization...
Shares of semiconductor lithography specialist ASML Holding (NASDAQ: ASML) have more than doubled over the last year -- crushing the performance of the broader tech sector and Nasdaq Composite . At $1,410 per share at the time of this writing, ASML would need to gain around 42% to surpass $2,000 per share, and 81% to become the first European company to surpass $1 trillion in market capitalization . Here's why ASML's investment thesis is stronger than ever, and what could hold the tech stock back from surpassing $2,000 per share. Image source: Getty Images. Continue reading
In this article AAPL Follow your favorite stocks CREATE FREE ACCOUNT Steve Jobs (R), Apple Inc. CEO, and Tim Cook, Apple Inc. Coo, speak at a press conference at Apple headquarters in Cupertino, California. Kimberly White | Corbis Historical | Getty Images In his time running Apple, Tim Cook has been more like the "president of a country, not a company," according to Deepwater Asset Management's G...
In this article AAPL Follow your favorite stocks CREATE FREE ACCOUNT Steve Jobs (R), Apple Inc. CEO, and Tim Cook, Apple Inc. Coo, speak at a press conference at Apple headquarters in Cupertino, California. Kimberly White | Corbis Historical | Getty Images In his time running Apple, Tim Cook has been more like the "president of a country, not a company," according to Deepwater Asset Management's Gene Munster. Cook's predecessor, Steve Jobs , is considered one of the great product innovators in modern American history. But the role has been a very different one since Jobs stepped down in 2011, shortly before he died from cancer, and tapped Cook to take over. With his run as CEO coming to an end on Sept. 1, Cook's legacy will be one of tremendous value creation — Apple's market cap increased from about $350 billion to $4 trillion on his watch — even if the company's products were more evolutionary than revolutionary during his 15-year run. That Cook, 65, is handing the reins to longtime hardware boss John Ternus is no great surprise. Multiple news outlets profiled Ternus in recent months, with The New York Times running a story in January headlined, "The Man Who Could Be Apple’s Next C.E.O." Still, the move is taking place "about two years earlier than what I was expecting," Munster told CNBC's "Closing Bell: Overtime" after the news broke on Monday. Munster said Cook has cleverly navigated the Trump administration's tariff policies, which posed a particular threat to Apple because of how much the company counts on China for the manufacturing of its devices. watch now VIDEO 4:24 04:24 Apple CEO Tim Cook leaving position 'sooner than expected', says Deepwater's Gene Munster Closing Bell: Overtime Far from suffering since Trump's second White House term began in January 2025, Apple's stock is up about 20%, and Cook hasn't been shy at all about cozying up to the president in ways meant to charm the commander in chief. In August, Cook joined Trump at an event in the Oval ...